Complement-induced protection: An explanation for the limitations of cell-based tumour immunotherapies

Immunology and Cell Biology

Volumn 90, Issue 9, 2012, Pages 869-871

  Kempshall, Emma ^a   Thebault, Simon ^a   Paul Morgan, B ^a   Harris, Claire L ^a   Gallimore, Awen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CD8+ T cell; Complement; immunotherapy; induced protection; MAC; NK; tumour

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; GAMMA INTERFERON; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL KILLING; CELL PROTECTION; COMPLEMENT SYSTEM; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; NATURAL KILLER T CELL; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASMS; PERFORIN; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

ANIMALIA;

EID: 84867741869     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.30     Document Type: Article

References (34)

1. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010; 10: 369-373.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
3. Walport MJ. Complement. first of two parts. N Engl J Med 2001; 344: 1058-1066.
4. Morgan BP, Meri S. Membrane-proteins that protect against complement lysis. Springer Semin Immun 1994; 15: 369-396. (Pubitemid 24040807)
5. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992; 140: 1039-1043.
6. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J et al. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996; 27: 1329-1335. (Pubitemid 26415328)
7. Kitano E, Kitamura H. Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines. Clin Exp Immunol 1993; 94: 273-278. (Pubitemid 23337826)
8. Barnum SR, Ishii Y, Agrawal A, Volanakis JE. Production and interferon-gammamediated regulation of complement component C2 and factors B and D by the astroglioma cell line U105-MG. Biochem J 1992; 287(Part 2): 595-601.
9. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123. (Pubitemid 36959821)
10. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999; 20: 576-582.
11. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-1235.
12. Turner RTO. The role of complement in tumour formation: friend or foe [PhD thesis] Cardiff: Cardiff University, 2010. Available from the Health library, Cardiff University. http://library.cardiff.ac.uk/vwebv/holdingsInfo? bibId=889882.
13. Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol 2009; 46: 2794-2800.
14. Koretz K, Bruderlein S, Henne C, Moller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993; 68: 926-931. (Pubitemid 23315225)
15. Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: A preventive mechanism of malignant tumor cells against complement attack? Breast Cancer Res Treat 1994; 32: 213-219. (Pubitemid 24313346)
16. Madjd Z, Durrant LG, Bradley R, Spendlove I, Ellis IO, Pinder SE. Loss of CD55 is associated with aggressive breast tumors. Clin Cancer Res 2004; 10: 2797-2803. (Pubitemid 38509158)
17. Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I. Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 2006; 55: 973-980. (Pubitemid 43673588)
18. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 2003; 52: 638-642. (Pubitemid 37268197)
19. Xu L, Shao H, Wu W, Cao Z, Zhao Z, Liu H et al. Co-expression of the complement regulatory proteins human DAF and CD59 with an IRES-mediated dicistronic mammalian vector enhances their cell protective effects. Int J Mol Med 2005; 16: 409-414.
20. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S et al. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 2005; 62: 224-232. (Pubitemid 40129060)
21. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor-cells from lytic doses of antibody and complement. Eur J Immunol 1992; 22: 1207-1213.
22. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol 1995; 155: 2203-2210.
23. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000; 97: 2731-2736. (Pubitemid 30159240)
24. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320-2328. (Pubitemid 27251014)
25. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738. (Pubitemid 35177960)
26. Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007; 109: 323-330. (Pubitemid 46053073)
27. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964. (Pubitemid 44498003)
28. Rosenberg SA. Shedding light on immunotherapy for cancer. New Engl J Med 2004; 350: 1461-1463. (Pubitemid 38420003)
29. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192: 755-760.
30. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184: 1781-1790. (Pubitemid 26404469)
31. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999; 162: 6658-6662. (Pubitemid 29309390)
32. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012; 188: 2630-2642.
33. van den Broek MF, Kagi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol 1995; 25: 3514-3516. (Pubitemid 26004963)
34. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25: 1265-1275. (Pubitemid 350089828)